MedTrace Logo

Association Between Helioderma and Response to Immunotherapy in Patients With Metastatic Melanoma

NCT05641012 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-12-07

No results posted yet for this study

Summary

Melanoma is one of the most aggressive forms of skin cancer, representing only 5% of all skin cancer but 80% of all death by skin cancer. Diagnosis and treatment of melanoma must be early because prognosis depends on stage disease.

Immunotherapy is used in metastatic melanoma. However, all patients not respond to immunotherapy.

Helioderma (photoaging) is a marker of exposure to UV rays and therefore of mutagenesis. Thus, helioderma could be associated with the response to immunotherapy.

Conditions

Interventions

OTHER

data collection

helioderma evaluation

Sponsors & Collaborators

  • Université de Reims Champagne-Ardenne

    collaborator OTHER

  • Institut Jean-Godinot

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2024-12-01
Completion
2025-05-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05641012 on ClinicalTrials.gov